Low Dose Naltrexone in Charleston and Mt. Pleasant, SC

Reviewed by Ashley Harwyn, PA-C, ABAAHP  |  A4M Board Certified  |  Updated October 4, 2026

LDN is an off-label, low-dose use of naltrexone with small and mixed evidence. Here is what the trials found, who should avoid it, and how a careful trial works.

So does it work? For a few conditions there are small studies with encouraging results, but larger and better-controlled trials have often failed to confirm them.[2][4][5] A 2026 review of 105 studies, including 15 randomized trials, concluded that current evidence does not support routine use, while leaving room for a careful trial when standard treatments have not helped.[2] That is the frame we use. If you are curious about LDN, we start with your full history through our functional medicine evaluation, explain the evidence for your specific condition, and only then decide together whether a trial makes sense.

• LDN is off-label. Naltrexone is FDA-approved at 50 mg daily for alcohol dependence and opioid blockade, not at low doses or for other conditions.[1]
• Research doses range from about 0.5 to 6 mg a day, with 4.5 mg the dose used in most studies.[2]
• The evidence is small and mixed. Early fibromyalgia studies looked promising, but two larger placebo-controlled trials found no meaningful pain benefit.[3][4][5]
• A Cochrane review of LDN for active Crohn's disease rated the evidence as low certainty and found it insufficient for firm conclusions.[6]
• Naltrexone blocks opioid pain medicines and can trigger withdrawal in anyone taking opioids, so every clinician who treats you needs to know you take it.[1]
• Reported side effects at low doses are usually mild: trouble sleeping, vivid dreams, nausea, and dizziness.[2]

What LDN is, and why “off-label” matters

Naltrexone blocks opioid receptors in the brain and body. At the standard 50 mg dose, that blockade is strong enough to stop opioid drugs from working, which is why it is approved for opioid and alcohol dependence.[1] LDN uses the same molecule at a much smaller dose. In our practice, the doses we discuss typically fall between 1.5 and 4.5 mg, which sits inside the range used in published research.[2]

Off-label prescribing is legal and common. It means a licensed clinician uses an approved drug for a purpose or dose the FDA has not reviewed. That does not make the drug unsafe, but no regulator has checked that it works for that purpose. The approved tablet comes only in a 50 mg strength, so low-dose supply comes mainly from compounding pharmacies.[1][2]

Why would a smaller dose do something different? Researchers have proposed several ideas, including brief, intermittent opioid-receptor blockade that prompts the body to adjust, and calming of immune cells in the nervous system called microglia.[2] These are hypotheses. They explain why scientists are interested, but they do not prove that LDN helps any particular person.

What the trials actually found

LDN has been studied in pain conditions, autoimmune disease, gut disease, skin conditions, mental health, and more.[2] The pattern across that research is consistent: small, open, or short studies tend to look positive, and larger placebo-controlled trials often do not repeat the result.[2] Fibromyalgia shows this most clearly, because it has the most trials.

Read the fibromyalgia rows in order and the story is plain. The 2013 crossover trial was small but encouraging: pain dropped more on LDN than on placebo, and mood and life satisfaction improved, though fatigue and sleep did not.[3] A Danish trial published in 2024 tested 6 mg a day in 99 women and found LDN was not superior to placebo for pain, with a possible signal for memory that the authors said needs its own study.[4] A Spanish trial published in 2026 followed 98 women for a full year on 4.5 mg and found no clinically meaningful benefit for pain-related outcomes.[5]

For Crohn's disease, one small adult study suggested better clinical and endoscopic response with LDN than with placebo. The Cochrane reviewers still rated the overall evidence as low certainty because the numbers were so small, and they called for more trials.[6] For multiple sclerosis, a 2010 pilot trial found improvements on mental health quality-of-life measures but not physical ones, and many people dropped out, which weakened the results.[7] Neither finding shows LDN changes the course of either disease.

What does that add up to? LDN is not a proven treatment for any of these conditions. It is a low-cost, generally well-tolerated option with uncertain benefit, which is the conclusion of the most recent broad review.[2] If someone tells you LDN is a proven cure for chronic pain or autoimmune disease, the trials above do not support it.

Safety first: LDN and opioid pain medicine

This is the most important section on the page. Naltrexone is an opioid blocker at any dose. The FDA label lists people taking opioid pain medicines, people who are physically dependent on opioids, and people in acute opioid withdrawal among those who must not take it.[1] In someone with opioids in their system, naltrexone can set off sudden withdrawal, and the label says this can be severe enough to need hospital care.[1]

There is a second risk that runs the other way. Trying to override the blockade with large amounts of opioids can lead to a life-threatening overdose, and after naltrexone is stopped, a person may respond to lower opioid doses than before.[1] The label also tells patients to make sure any treating physician knows they take naltrexone, especially in an emergency or when pain treatment is needed.[1]

In practice, that means a few habits matter:

• Tell every clinician, surgeon, dentist, and urgent care provider that you take LDN.
• If you have a planned surgery or procedure, ask well in advance when to pause LDN, so pain control is not blocked.
• Carry identification, such as a medication card, that tells medical staff you take naltrexone, as the label advises.[1]

The label also reports cases of hepatitis and liver dysfunction linked to naltrexone, so liver disease is something we review before any prescription.[1] At low doses, the side effects reported in research are usually mild and short-lived, most often trouble sleeping, vivid dreams, nausea, and dizziness.[2] In the year-long fibromyalgia trial, mostly mild adverse events were reported at similar rates on LDN and placebo, 68.8% versus 72%, with no treatment-related serious events.[5]

Wondering if LDN is safe with your other medicines? That question comes before any prescription. Call 843-981-0870 and we will review what you take, any procedures on your calendar, and whether an LDN trial is reasonable for you.

Who might consider a trial, and who should not

Because the evidence is limited, LDN makes the most sense as an add-on to good standard care, not a replacement for it. The 2026 review describes a reasonable role in treatment-resistant cases where standard therapies have failed, provided the experimental status and uncertain benefit are explained up front.[2] That is the same line we draw.

A conversation about LDN may be reasonable if you:

• Live with a chronic condition such as fibromyalgia that has not responded well to standard treatment.
• Understand that the drug is off-label and that the best trials have been mixed.
• Take no opioid medicines now and have none planned, and can commit to telling every provider about it.
• Want a time-limited trial with a clear way to judge whether it is helping.

LDN is not the right choice if you take opioid pain medicine, are maintained on methadone or buprenorphine, are in opioid withdrawal, or have significant liver disease without specialist input.[1] It also should not replace proven treatment. If you have multiple sclerosis or Crohn's disease, your neurologist or gastroenterologist should stay in charge of disease-modifying care, and any LDN trial should be shared with them. For persistent low mood, effective treatment exists, and our mental health care is a better first stop than an off-label drug.

How an LDN trial works with us

A trial starts with a full visit, not a quick refill. Ashley Harwyn, PA-C, who is board certified in anti-aging and functional medicine (A4M) and holds ABAAHP certification, reviews your diagnosis, past treatments, every medicine and supplement you take, and any upcoming procedures. Recent labs, including liver tests, help set a safe baseline, and annual full panel labs can cover that if you have none.

If LDN fits, we agree on one or two specific goals before you start, such as a pain score you track daily or a symptom that limits your week. The research trials judged results over 8 to 12 weeks or longer, so we set a similar review point rather than adjusting things day by day.[4][7] The prescription is filled by a compounding pharmacy at the dose we choose together, starting low. If your tracked goal has not clearly improved by the review visit, we stop, and that result counts as useful information too.

You can see Ashley in Mount Pleasant at 496 Bramson Ct, Suite 120, or downtown at The Longevity Club, 163 Rutledge Ave, Suite 202, in Charleston. Nutrition and gut health often matter in chronic pain and inflammation, so a nutritional therapy plan may run alongside any trial.